Finance

Lists
Q3 2026 earnings • in 2 days
See details
PACB:NASDAQ
Pacific Biosciences of California Inc
$2.34
-9.98%
(-0.26) 1D
$2.34
-0.21% (-0.0050)
After hours
Closed: Nov 2, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PACB...
Open
$2.68
High
$2.72
Low
$2.31
Mkt. cap
727.50M
Avg. vol.
18.13M
Volume
0.00
52-wk high
$3.44
52-wk low
$1.07
EPS
-$0.43
Beta
2.19
Shares outstanding
310.83M
No. of employees
485
Open
$2.68
High
$2.72
Low
$2.31
Mkt. cap
727.50M
Avg. vol.
18.13M
Volume
0.00
52-wk high
$3.44
52-wk low
$1.07
EPS
-$0.43
Beta
2.19
Shares outstanding
310.83M
No. of employees
485
News stories
From web sources and news partners
Profile
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing, based on the properties of zero-mode waveguides and sequencing by binding chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension. Wikipedia
About Pacific Biosciences of California Inc
CEOChristian Henry
Employees485
Founded2004
HeadquartersMenlo Park, California, United States
SectorHealth care
Websitepacb.com
Analyst ratings
Based on 6 analysts giving stock ratings to PACB in the past 3 months
Buy
Buy
3
Hold
2
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for PACB in the last 3 months.
Highest
Current $2.34
$3.00 (+27.93%)
Average
$2.02 (-13.86%)
Lowest
$1.25 (-46.70%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mason Carrico
Stephens
Buy
Maintained
$2.50
+6.6%
10/23/2026
Luke Sergott
Barclays
Sell
Maintained
$1.25
-46.7%
10/07/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Reiterated
-
-
09/11/2026
Unknown Analyst
UBS
Hold
Initiated
$1.35
-42.4%
09/08/2026
Doug Schenkel
UBS
Hold
Maintained
$1.35
-42.4%
09/09/2026
David Westenberg
Piper Sandler
Hold
Reiterated
$2.00
-14.7%
08/06/2026
Daniel Brennan
TD Cowen
Buy
Maintained
$3.00
+27.9%
08/06/2026
Subbu Nambi
Guggenheim
Hold
Maintained
-
-
02/12/2026
Next call in 36:36:08
Wed, Nov 4, 4:30 PM
Fiscal period
Q3 2026
- / -$0.13
Revenue / Est. (USD)
- / 39.46M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
38.44M
44.64M
37.18M
39.01M
Cost of goods sold
22.28M
40.28M
23.65M
26.19M
Cost of revenue
22.28M
40.28M
23.65M
26.19M
Research and development expenses
22.85M
23.48M
19.61M
23.02M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
31.10M
35.75M
31.15M
33.39M
Operating expense
54.96M
64.42M
51.78M
57.43M
Total operating expenses
77.24M
104.71M
75.43M
83.62M
Operating income
-38.80M
-60.06M
-38.25M
-44.61M
Other non operating income
2.92M
6.48M
1.71M
2.04M
EBT including unusual items
-37.62M
-40.17M
-8.09M
-44.68M
EBT excluding unusual items
-37.62M
-55.33M
-38.28M
-44.68M
Income tax expense
383.00K
202.00K
184.00K
58.00K
Effective tax rate
-1.02%
-0.50%
-2.27%
-0.13%
Other operating expenses
-
4.18M
-
-
Net income
-38.00M
-40.37M
-8.28M
-44.74M
Net profit margin
-98.85%
-90.43%
-22.26%
-114.70%
Earnings per share
-0.12
-0.12
-0.12
-0.14
Interest and investment income
-
-
-
-
Interest expense
-1.74M
-1.74M
-1.74M
-2.11M
Net interest expenses
-1.74M
-1.74M
-1.74M
-2.11M
Depreciation and amortization charges
-
-
-
-
EBITDA
-35.32M
-56.31M
-35.03M
-40.75M
Gain or loss from assets sale
-
-
-48.10M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps